In conclusion, the results of the present study revealed that anti-TNFR2 and anti-PD-L1 combination therapy boosted tumor eradication by inhibiting the growth of tumors, relieving tumor immunosuppression, and generating robust memory recall. The gene discussed is CD274; the disease is neoplasm.